Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A Treatment IND for 566C80 Therapy of Pneumocystis carinii Pneumonia Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about A Treatment IND for 566C80 Therapy of Pneumocystis carinii Pneumonia conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Treatment IND for 566C80 Therapy of Pneumocystis carinii Pneumonia Clinical research trials and A Treatment IND for 566C80 Therapy of Pneumocystis carinii Pneumonia medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as A Treatment IND for 566C80 Therapy of Pneumocystis carinii Pneumonia. A Treatment IND for 566C80 Therapy of Pneumocystis carinii Pneumonia Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a A Treatment IND for 566C80 Therapy of Pneumocystis carinii Pneumonia clinical trial. Participants frequently get the best healthcare available for their A Treatment IND for 566C80 Therapy of Pneumocystis carinii Pneumonia condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.

Home > "A" Clinical Trials Conditions > A Treatment IND for 566C80 Therapy of Pneumocystis carinii Pneumonia

A Treatment IND for 566C80 Therapy of Pneumocystis carinii Pneumonia



A Treatment IND for 566C80 Therapy of Pneumocystis carinii Pneumonia

For Condition: Pneumonia, Pneumocystis carinii,HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: To facilitate provision of atovaquone (566C80) to patients who have mild to moderate Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole (TMP / SMX ); to monitor serious adverse events attributable to 566C80.
Details:
Eligibility:
Study Type:  Interventional, Treatment, Open Label
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have the following: - Clinical diagnosis of acute mild to moderate Pneumocystis carinii pneumonia. - Dose-limiting intolerance to TMP / SMX or inadequate response to TMP / SMX. - Willingness and ability to give informed consent. The clinical condition of the patient and appropriate physiologic criteria should be used in evaluating patients for therapy with 566C80. Patients who are rapidly progressing in disease severity or have severe disease as evidenced by sustained tachypnea (e.g., sustained respiratory rate > 30 breaths/minute), rapid deterioration in (A-a)DO2 and chest radiograph may not be appropriate candidates for oral therapy, including 566C80. Therapy with parenteral pentamidine should be undertaken in these cases. Treatment with IV trimetrexate or primaquine / clindamycin should be considered for these patients unless the patient is known to have dose-limiting intolerance to these agents. Patients with severe PCP who are intolerant and/or unresponsive to therapy with TMP / SMX and parenteral pentamidine may enroll in the 566C80 open-label compassionate plea protocol. Exclusion Criteria Patients with the following prior conditions are excluded: History of serious or dose-limiting adverse experience during previous 566C80 therapy, thought to be attributable to the drug.
Total Enrollment: 

Location and Contact Information:

Glaxo Wellcome Inc
Research Triangle Park,  North Carolina,  27709
United States
 


Additional Information:
Study ID Numbers:  107A;  566-501
Study Start Date: 
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001991

Other Hiv Infections Studies:
1. Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination with Nucleoside Analogs: A Rollover Study for ACTG 320

2. A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients

3. A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children

4. Emtricitabine Given Once A Day with Other Anti-HIV Drugs in Children with HIV

5. Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients

Related Studies:

Other HIV Infections Clinical Trials
Other North Carolina Clinical Trials
Other Research Triangle Park Clinical Trials

A Treatment IND for 566C80 Therapy of Pneumocystis carinii Pneumonia
Modify your Search

  Other HIV Infections Clinical Trials
  Other North Carolina Clinical Trials
  Other Research Triangle Park Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103